Komori
Astellas Pharma (4503) · InitiativeAdvanced

Strengthening the oversight function of the Audit and Supervisory Committee Office

First written in FY2020. 2 of 3 entries say "Advanced", first in FY2021. Latest entry: FY2022.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY2021 – FY20222020: 120202021: 120212022: 12022
Same theme, other companies
Support for the Audit & Supervisory Committee by the Audit & Supervisory Committee OfficeA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

0 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Moved together

"Maximizing Product Value" moved the same way as this thread, in the same document, in 2 of its 3 moves.

222222★123456
  1. ★This thread
  2. 1Maximizing Product Value2×
  3. 2Pursuit of Operational Excellence2×
  4. 3Enhancing Stable, Sustainable Shareholder Returns2×
  5. 4Regulatory Submission and Approval Progress Across the Clinical Development Pipeline2×
  6. 5Network-Based Research Leveraging External Resources2×
  7. 6Expansion into muscle diseases, ophthalmology and cell therapy2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.